The Platform on Benefit Assessment* is an EAA-affiliated multi-stakeholder initiative focusing on HTA in Germany (AMNOG).
Download the English Versions of the Platform on Benefit Assessment Proceedings below
#22 ATMP and Orphan Diseases: Data sources beyond RCTs
#21 EU Pharma Regulation - Impulse for Germany
#20 Which endpoints are patient-relevant?
#19 Interaction between HTA and authorisation
#18 AMNOG 2.0: On the path to an efficient system
#17 Impact of EU HTA on the AMNOG procedure
#16 AMNOG financial stabilisation - new treatment paradigms
#15 Further development of the AMNOG with a sense of proportion and evidence
#14 Guidelines - their role in AMNOG and medical care
#13 Patients and Medical Societies: Additional Expertise for AMNOG
#12 Digital Health Data: Benefits, Costs, Governance
#11 European HTA Procedure: Advances and Pitfalls
#10 What are the (additional) benefits of registry data?
#9 Contextual Evidence - Strategies for Targeted Therapy
#8 European Benefit Assessment - Opportunities and Risks
#7 Physician Information via Software: Orientation or Control?
#6 Physician Information via software: Ways and Goals
#5 Evidence Gaps - What does Registry Data Offer?
#4 AMNOG 2.0 - Information Problems
#3 Adaptive Pathways - Opportunities and Risks
#2 Clinical Studies - which endpoints count?
* The German Platform on Benefit Assessment is a collaboration between Springer Medicine (Springer Nature Group) with AbbVie Deutschland, DAK Gesundheit, MSD Sharp & Dohme, Novo Nordisk, Roche Pharma, vfa, Cencora.